SCYX — SCYNEXIS INC
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1178253 ·
Last close
$4.23
Market Cap
$336.04M
52W High
$9.12
52W Low
$4.15
ADV30
58,823
Next earnings
2026-05-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -16,939,000 | -21,299,000 | 77,626,000 | 36,671,000 | 36,319,000 |
| Dec 2025 | 18,646,000 | — | 10,521,000 | 12,258,000 | 59,027,000 | 21,259,000 | 9,651,000 |
| Sep 2025 | 334,000 | — | -8,405,000 | -8,591,000 | 51,071,000 | 14,797,000 | 14,641,000 |
| Jun 2025 | 1,364,000 | — | -9,561,000 | -6,885,000 | 60,694,000 | 11,020,000 | 16,227,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,919,000
Investing CF
$11,341,000
Financing CF
$23,952,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-6.72
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-385,144,000
Inventory
—
Receivables
$0
ST Investments
$18,772,000
EBIT TTM
$-8,436,000
Pretax Income TTM
$-8,609,000
Interest Exp TTM
$173,000
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$20,344,000
EBITDA
—
Free Cash Flow
$2,650,125
Enterprise Value
$-15,196,708
Total Cash
$59,263,000
Total Debt
$2,061,000
Shares Out
79,442,633
Trailing EPS
$-3.84
Book Value
$0.67
ROE
-53.4%
ROA
-21.0%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 20,601,000 | -16,074,000 | -8,609,000 | 59,027,000 | 9,651,000 | — | -5,283,000 |
| Dec 2024 | 3,746,000 | -37,117,000 | -21,288,000 | 90,643,000 | 35,566,000 | — | -24,009,000 |
| Dec 2023 | 140,141,000 | 72,669,000 | 67,041,000 | 128,412,000 | 55,450,000 | — | 60,159,000 |
| Dec 2022 | 5,091,000 | -85,757,000 | -62,809,000 | 87,810,000 | 84,577,000 | — | -79,883,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$4,948,000
NetIncome TTM
$-18,700,000
OpCashFlow TTM
$0
Assets (Latest)
$90,643,000
Forward EPS
$-2.52
Max Pain — expiry 2026-06-18
max pain strike: $2.50 · spot: $4.09 · call oi: 1,091 · put oi: 1
Expected Move to 2026-06-18:
±$2.38
(58.07%) —
implied range
$1.72 –
$6.47
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CATX | Perspective Therapeutics, Inc. | $336.44M | $2.95 | — |
| IRD | Opus Genetics, Inc. | $333.57M | $4.04 | — |
| UPB | Upstream Bio, Inc. | $331.96M | $6.10 | — |
| NWBO | NORTHWEST BIOTHERAPEUTICS INC | $328.67M | $0.20 | — |
| ENTA | ENANTA PHARMACEUTICALS INC | $346.03M | $11.90 | — |
News headlines (Yahoo Finance, 1h cache)
Upcoming Stock Splits This Week (June 1 to June 5) – Stay Invested
2026-06-01 06:14 · Yahoo
SCYNEXIS Announces One-for-Eight Reverse Stock Split
2026-05-22 20:15 · Yahoo
SCYNEXIS Reports First Quarter 2026 Financial Results and Provides Corporate Update
2026-05-11 20:23 · Yahoo
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
2026-05-07 01:15 · Yahoo
SCYNEXIS Enters $40 Million Private Placement, Completes Acquisition of PXL-770 to Treat Kidney Disease
2026-03-31 11:59 · Yahoo
SCYNEXIS Announces $40.0 Million Private Placement
2026-03-31 10:45 · Yahoo
SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)
2026-03-31 10:40 · Yahoo
SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy
2026-03-12 07:38 · Yahoo
Scynexis: Q4 Earnings Snapshot
2026-03-04 22:36 · Yahoo
SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update
2026-03-04 21:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.